Intrauterine 10μg and 20μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: Clinical, endometrial and metabolic response

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 109, Issue 2, 2002, Pages 136-144

  Raudaskoski, T ^a   Tapanainen, J ^a   Tomas E ^b   Luotola, H ^c   Pekonen, F ^d   Ronni Sivula, H ^e   Timonen, H ^g   Riphagen, F ^f   Laatikainen, T ^g  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Gyne Praxis   (Finland)

^d Medical Centre Femeda   (Finland)

^e Med Centre Keskustornin Gynekologit   (Finland)

^f Oy Leiras Finland Ab   (Finland)

^g PL 24 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN; LEVONORGESTREL; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; TRIACYLGLYCEROL; DRUG DERIVATIVE; ESTRADIOL; ESTRADIOL VALERATE; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE; PROGESTERONE DERIVATIVE; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; BIOPSY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WITHDRAWAL BLEEDING; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; INTRAUTERINE CONTRACEPTIVE DEVICE; INTRAVAGINAL DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; UTERUS BLEEDING;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DINOPROSTONE; DRUG THERAPY, COMBINATION; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MEDROXYPROGESTERONE; MIDDLE AGED; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 0036480588     PISSN: 14700328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-0328(02)01167-9     Document Type: Article

References (36)

1. Grady D., Gebretsadik T., Kerlikowske K., Ernster V., Petitte D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 85:1995;304-312.
2. Smith R.N., Holland E.F., Studd J.W. The symptomatology of progestogen intolerance. Maturitas. 18:1994;87-91.
3. Samsioe G. Hormone replacement therapy: aspects of bleeding problems and compliance. Int J Fertil Menopausal Stud. 41:1996;11-15.
4. Stadberg E., Mattsson L.A., Milsom I. Women's attitudes and knowledge about the climacteric period and its treatment. A Swedish population-based study. Maturitas. 27:1997;109-116.
5. Karakoc B., Erenus M. Compliance considerations with hormone replacement therapy. Menopause. 5:1998;102-106.
6. Jensen L.C., Obel E.B., Lindhard A., Steendahl E., Fink B. Frequency of curettage in middle-aged women treated with sequential preparations versus untreated women. Maturitas. 15:1992;61-69.
7. Ettinger B., Selby J.V., Citron J.T., Ettinger V.M., Zhang D. Gynecologic complications of cyclic estrogen progestin therapy. Maturitas. 17:1993;197-204.
8. Staland B. Continuous treatment with natural oestrogens and progestogens: a method to avoid endometrial stimulation. Maturitas. 3:1981;145-151.
9. Weiderpass E., Adami H.O., Baron JAet al. Risk of endometrial cancer following oestrogen replacement with and without progestins. J Natl Cancer Institute. 91:1999;1131-1137.
10. Ettinger B., Li D.K., Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cyclic versus continuous combined schedules. Fertil Steril. 69:1998;859-865.
11. Andersson K., Mattsson L-A, Rybo G., Stadberg E. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Am J Obstet Gynecol. 79:1992;963-967.
12. Raudaskoski T., Lahti E., Kauppila A., Apaja-Sarkkinen M., Laatikainen T. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: Clinical and endometrial responses. Am J Obstet Gynecol. 172:1995;114-119.
13. Riphagen F.E. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric. 3:2000;199-212.
14. Hirvonen E., Mälkönen M., Manninen V. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestagen regimens in post-menopausal women. Maturitas. 9:1987;69-79.
15. Graff-Iversen S., Stensvold I., Lund-Larsen P.G., Nodarse L.O., Tverdal A., Urdal P. Serum lipids in postmenopausal or perimenopausal women using estrogen alone, estrogen with levonorgestrel, or estrogen with norethisterone, compared with nonusers: results from a cross sectional study in two Norwegian counties 1985-1988. J Clin Epidemiol. 51:1998;1311-1316.
16. Raudaskoski T., Tomas E., Paakkari I., Kauppila A., Laatikainen T. Serum lipids and lipoproteins in postmenopausal women receiving transdermal oestrogen in combination with a levonorgestrel-releasing intrauterine device. Maturitas. 22:1995;47-53.
17. Kurman R. Blaustein's Pathology of the Female Genital Tract. 1994;466-471 Springer-Verlag, New York.
18. Zaino RJ. Interpretation of Endometrial Biopsies and Curettages. Biopsy Interpretation Series. NewYork: Lippincott-Raven, 1996: 143-173.
19. Mertens R., Liedtke R.J., Batjer J.D. Evaluation of a radioimmunoassay for estradiol in unextracted serum. Clin Chem. 29:1983;1961-1963.
20. Nilsson C.G., Lähteenmäki P., Luukkainen T. Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year of treatment with a levonorgestrel-IUD. Contraception. 21:1980;225-233.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
22. Wollter-Svensson L-O, Stadberg E., Andersson K., Mattsson L-Å, Odling V., Persson I. Intrauterine administration of levonorgestrel 5 and 10μg/24 hours in perimenopausal hormone replacement therapy. Acta Obstet Gynecol Scand. 76:1997;449-454.
23. Suhonen S., Holmström T., Allonen H.O., Lähteenmäki P. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril. 63:1995;336-342.
24. Raudaskoski T., Laatikainen T., Kauppila A. Sex-hormone binding globulin as an indicator of the hepatic impacts of continuous combined hormone replacement regimens. Maturitas. 29:1998;87-92.
25. Xiao B., Zhou L., Zhang X., Jia M., Luukkainen T., Allonen H. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception. 41:1990;353-362.
26. Jia M.C., Zhou L.Y., Ren S., Dong L., Xiao B. Serum SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Advances in Contraception. 8:1992;33-40.
27. Suvanto-Luukkonen E., Sundström H., Penttinen J., Läärä E., Pramila S., Kauppila A. Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 26:1997;211-217.
28. Udoff L., Langenberg P., Adashi E.Y. Combined continuous hormone replacement therapy: a critical review. Obstet Gynecol. 86:1995;306-316.
29. Mattsson L-Å, Bohnet H.G., Gredmark T., Torhorst J., Hornig F., Huls G. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. Obstet Gynecol. 94:1999;61-65.
30. Byrjalsen I., Thormann L., Meinecke B., Riis B.J., Christiansen C. Sequential estrogen and progestogen therapy: assessment of progestational effects on the postmenopausal endometrium. Obstet Gynecol. 79:1992;523-528.
31. Walsh J.M., Grady D. Treatment of hyperlipidemia in women. JAMA. 274:1995;1152-1158.
32. Bass K.M., Newschaffer C.J., Klag M.J., Bush T.L. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med. 153:1993;2209-2216.
33. Wollter-Svensson L-O, Stadberg E., Andersson K., Mattsson L-Å, Odling V., Persson I. Intrauterine administration of levonorgestrel in two low doses in HRT. A randomized clinical trial during one year: effects on lipid and lipoprotein metabolism. Maturitas. 22:1995;199-205.
34. Crook D., Cust M.P., Gangar KFet al. Comparison of transdermal and oral estrogen-progestin replacement therapy: Effects on serum lipids and lipoproteins. Am J Obstet Gynecol. 166:1992;950-955.
35. Maher V.M.G., Brown B.G. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 6:1995;229-235.
36. Andersson K., Odling V., Rybo G. Levonorgestrel-releasing and copper-releasing (NovaT) IUDs during five years use: a randomized comparative trial. Contraception. 49:1994;56-72.